John R Lydeard - JoVE Visualize

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Molecular Therapy. Methods & Clinical Development|November 29, 2023

Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicityJohn R Lydeard, Michelle I Lin, Huanying Gary Ge, et al.

Nature|July 22, 2014

Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomideEric S Fischer, Kerstin Böhm, John R Lydeard, et al.

Blood|February 4, 2026

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCTMuhammad Umair Mushtaq, John F DiPersio, Jacques Azzi, et al.

Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Molecular Therapy. Methods & Clinical Development|November 29, 2023

Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicityJohn R Lydeard, Michelle I Lin, Huanying Gary Ge, et al.

Nature|July 22, 2014

Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomideEric S Fischer, Kerstin Böhm, John R Lydeard, et al.

Blood|February 4, 2026

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCTMuhammad Umair Mushtaq, John F DiPersio, Jacques Azzi, et al.

Pageof 2